AtriCure, Inc. (NASDAQ:ATRC) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of AtriCure, Inc. (NASDAQ:ATRC) have been assigned an average recommendation of “Moderate Buy” from the twelve analysts that are covering the firm, MarketBeat.com reports. Four analysts have rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $52.00.

Several analysts have issued reports on the company. Raymond James Financial set a $52.00 target price on AtriCure in a research note on Tuesday, July 21st. Zacks Research downgraded AtriCure from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 24th. BTIG Research lifted their price objective on AtriCure from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Monday, August 24th. UBS Group dropped their price objective on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, July 28th. Finally, Citigroup reiterated a “market outperform” rating on shares of AtriCure in a research report on Tuesday, July 21st.

AtriCure Price Performance

ATRC opened at $51.52 on Tuesday. AtriCure has a twelve month low of $25.36 and a twelve month high of $53.50. The company’s 50-day moving average price is $40.56 and its two-hundred day moving average price is $32.96. The stock has a market cap of $2.62 billion, a price-to-earnings ratio of 245.35 and a beta of 1.26. The company has a quick ratio of 3.19, a current ratio of 4.22 and a debt-to-equity ratio of 0.14.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The company had revenue of $153.60 million during the quarter, compared to analyst estimates of $151.80 million. During the same quarter last year, the business posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, equities analysts expect that AtriCure will post 0.29 earnings per share for the current year.

Insider Activity at AtriCure

In related news, insider Karl S. Dahlquist sold 9,370 shares of AtriCure stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $48.89, for a total value of $458,099.30. Following the completion of the transaction, the insider directly owned 87,319 shares in the company, valued at approximately $4,269,025.91. The trade was a 9.69% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Karen Prange sold 3,564 shares of the business’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $38.80, for a total transaction of $138,283.20. Following the sale, the director directly owned 22,809 shares in the company, valued at $884,989.20. The trade was a 13.51% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 61,379 shares of company stock worth $2,557,552 in the last ninety days. Insiders own 4.00% of the company’s stock.

Institutional Trading of AtriCure

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE grew its holdings in AtriCure by 13.7% during the 1st quarter. Bank of America Corp DE now owns 768,561 shares of the medical device company’s stock valued at $21,927,000 after buying an additional 92,830 shares in the last quarter. Man Group plc purchased a new stake in shares of AtriCure in the second quarter worth about $684,000. Assenagon Asset Management S.A. bought a new position in shares of AtriCure in the second quarter valued at approximately $1,744,000. Rice Hall James & Associates LLC bought a new position in shares of AtriCure in the second quarter valued at approximately $3,755,000. Finally, F m Investments LLC purchased a new position in AtriCure during the fourth quarter valued at approximately $2,872,000. 99.11% of the stock is currently owned by institutional investors.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.